Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hye Won | - |
dc.contributor.author | Kwon, Whi-An | - |
dc.contributor.author | Nguyen, La Ngoc Thu | - |
dc.contributor.author | Phan, Do Thanh Truc | - |
dc.contributor.author | Seo, Ho Kyung | - |
dc.date.accessioned | 2023-05-03T09:56:08Z | - |
dc.date.available | 2023-05-03T09:56:08Z | - |
dc.date.created | 2023-03-08 | - |
dc.date.issued | 2023-02 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/184967 | - |
dc.description.abstract | In the surgical oncology field, the change from a past radical surgery to an organ preserving surgery is a big trend. In muscle-invasive bladder cancer treatment, neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for muscle-invasive bladder cancer (MIBC) patients eligible for cisplatin. There is a growing interest in bladder preserving strategies after NAC because good oncologic outcome has been reported for pathologic complete response (pCR) patients after NAC, and many studies have continued to discuss whether bladder preservation treatment is possible for these patients. However, in actual clinical practice, decision-making should be determined according to clinical staging and there is a gap that cannot be ignored between clinical complete response (cCR) and pCR. Currently, there is a lack in a uniform approach to post-NAC restaging of MIBC and a standardized cCR definition. In this review, we clarify the gap between cCR and pCR at the current situation and focus on emerging strategies in bladder preservation in selected patients with MIBC who achieve cCR following NAC. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kwon, Whi-An | - |
dc.identifier.doi | 10.3390/cancers15041323 | - |
dc.identifier.scopusid | 2-s2.0-85149025891 | - |
dc.identifier.wosid | 000944882400001 | - |
dc.identifier.bibliographicCitation | CANCERS, v.15, no.4, pp.1 - 22 | - |
dc.relation.isPartOf | CANCERS | - |
dc.citation.title | CANCERS | - |
dc.citation.volume | 15 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 22 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TRANSITIONAL-CELL-CARCINOMA | - |
dc.subject.keywordPlus | LONG-TERM OUTCOMES | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | COMBINED-MODALITY TREATMENT | - |
dc.subject.keywordPlus | DOSE-DENSE METHOTREXATE | - |
dc.subject.keywordPlus | RADICAL CYSTECTOMY | - |
dc.subject.keywordPlus | TRIMODALITY THERAPY | - |
dc.subject.keywordPlus | PATHOLOGICAL STAGE | - |
dc.subject.keywordPlus | CISPLATIN SENSITIVITY | - |
dc.subject.keywordPlus | UROTHELIAL CARCINOMA | - |
dc.subject.keywordAuthor | muscle-invasive bladder cancer | - |
dc.subject.keywordAuthor | neoadjuvant chemotherapy | - |
dc.subject.keywordAuthor | radical cystectomy | - |
dc.subject.keywordAuthor | bladder preservation | - |
dc.subject.keywordAuthor | clinical complete response | - |
dc.identifier.url | https://www.mdpi.com/2072-6694/15/4/1323 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.